Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitorsNathan A. Brooks, Laurie A. LeBrun, Candace Langan et al.|Cancer Research|2025Cited by 0